PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.85%
Negative revenue growth while 3088.T stands at 4.56%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-2.33%
Negative gross profit growth while 3088.T is at 6.44%. Joel Greenblatt would examine cost competitiveness or demand decline.
-21.34%
Negative EBIT growth while 3088.T is at 18.53%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-23.85%
Negative operating income growth while 3088.T is at 15.21%. Joel Greenblatt would press for urgent turnaround measures.
-21.96%
Negative net income growth while 3088.T stands at 15.37%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-22.00%
Negative EPS growth while 3088.T is at 15.37%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.00%
Negative diluted EPS growth while 3088.T is at 15.38%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.06%
Slight or no buybacks while 3088.T is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.06%
Slight or no buyback while 3088.T is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
5.15%
OCF growth 1.25-1.5x 3088.T's 4.11%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
5.15%
FCF growth 1.25-1.5x 3088.T's 4.11%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
170.42%
10Y revenue/share CAGR 1.25-1.5x 3088.T's 115.91%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
62.00%
5Y revenue/share CAGR at 75-90% of 3088.T's 81.62%. Bill Ackman would encourage strategies to match competitor’s pace.
34.07%
3Y revenue/share CAGR under 50% of 3088.T's 82.03%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.06%
Below 50% of 3088.T's 405.20%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
23.20%
Below 50% of 3088.T's 179.27%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-9.07%
Negative 3Y CAGR while 3088.T is 135.90%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
341.28%
10Y equity/share CAGR 1.25-1.5x 3088.T's 249.35%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
88.66%
5Y equity/share CAGR at 50-75% of 3088.T's 130.75%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
40.10%
Below 50% of 3088.T's 109.14%. Michael Burry suspects a serious short-term disadvantage in building book value.
140.00%
10Y dividend/share CAGR at 50-75% of 3088.T's 233.33%. Martin Whitman suspects the firm lags in returning cash to shareholders over the decade.
166.67%
5Y dividend/share CAGR above 1.5x 3088.T's 66.67%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
9.09%
Below 50% of 3088.T's 42.86%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
5.48%
AR growth well above 3088.T's 2.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
6.87%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
0.24%
Asset growth well under 50% of 3088.T's 3.09%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
2.53%
Similar to 3088.T's 2.56%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-5.67%
We’re deleveraging while 3088.T stands at 0.32%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
2.76%
SG&A growth well above 3088.T's 1.69%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.